Richard S Levy
CIK 1454983 · EVP, Chief Drug Dev Officer · last filed 2026-08-04
Richard S Levy is an EVP, Chief Drug Dev Officer who has filed 106 SEC Form 4 insider transactions across 6 companies since 2009. The most recent filing, for KNSA, was dated Aug 4, 2026. Across all open-market trades the lifetime net is −$69.6M, making them a net seller over the disclosed history. Current disclosed insider exposure totals $15.9M across reported positions.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
$15.86M
6
106
-$69.59M
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| KNSA | Director | 22,359 | $79.49 | $1.78M | $0 | 15 | 2026-08-04 |
| KOD | Director | 250 | $40.65 | $10.2K | $44.3K | 10 | 2026-07-02 |
| MDGL | Director | 22,469 | $524.37 | $11.78M | -$19.89M | 23 | 2026-06-18 |
| TARA | Director | 51,000 | $3.98 | $203.0K | $127.6K | 10 | 2026-06-16 |
| CONSTELLATION PHARMACEUTICALS INC (CNST) Delisted | Director | — | $33.99 | — | $0 | 2 | 2021-06-04 |
| INCY | EVP, Chief Drug Dev Officer | 16,926 | $123.47 | $2.09M | -$49.87M | 40 | 2016-01-08 |
Recent Filings
106 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2026-08-04 | KNSA | Mixed | +403 | $0 | EDGAR |
| 2026-07-02 | KOD | Grant (A) | — | $0 | EDGAR |
| 2026-06-18 | MDGL | Grant (A) | +454 | $0 | EDGAR |
| 2026-06-16 | TARA | Grant (A) | — | $0 | EDGAR |
| 2026-06-02 | KNSA | Mixed | +2,799 | $0 | EDGAR |
| 2026-05-22 | MDGL | Notice (144) | −5,682 | -$2.92M | EDGAR |
| 2026-05-22 | MDGL | Sell (S) | −5,682 | -$2.93M | EDGAR |
| 2026-02-24 | MDGL | Exer (M) | +2,500 | $18.4K | EDGAR |
| 2026-02-04 | KNSA | Mixed | +683 | $0 | EDGAR |
| 2026-01-26 | MDGL | Exer (M) | +4,000 | $65.8K | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.